87282-07-3Relevant academic research and scientific papers
Catalytic Selective Oxidative Coupling of Secondary N-Alkylanilines: An Approach to Azoxyarene
Ke, Lei,Zhu, Guirong,Qian, Hui,Xiang, Guangya,Chen, Qin,Chen, Zhilong
supporting information, p. 4008 - 4013 (2019/06/04)
Azoxyarenes are among important scaffolds in organic molecules. Direct oxidative coupling of primary anilines provides a concise fashion to construct them. However, whether these scaffolds can be prepared from secondary N-alkylanilines is not well explored. Here, we present a catalytic selective oxidative coupling of secondary N-alkylaniline to afford azoxyarene with tungsten catalyst under mild conditions. In addition, azoxy can be viewed as a bioisostere of alkene and amide. Several "azoxyarene analogues" of the corresponding bioactive alkenes and amides showed comparable promising anticancer activities.
Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis
Ouvry, Gilles,Atrux-Tallau, Nicolas,Bihl, Franck,Bondu, Aline,Bouix-Peter, Claire,Carlavan, Isabelle,Christin, Olivier,Cuadrado, Marie-Josée,Defoin-Platel, Claire,Deret, Sophie,Duvert, Denis,Feret, Christophe,Forissier, Mathieu,Fournier, Jean-Fran?ois,Froude, David,Hacini-Rachinel, Fériel,Harris, Craig Steven,Hervouet, Catherine,Huguet, Hélène,Lafitte, Guillaume,Luzy, Anne-Pascale,Musicki, Branislav,Orfila, Danielle,Ozello, Benjamin,Pascau, Coralie,Pascau, Jonathan,Parnet, Véronique,Peluchon, Guillaume,Pierre, Romain,Piwnica, David,Raffin, Catherine,Rossio, Patricia,Spiesse, Delphine,Taquet, Nathalie,Thoreau, Etienne,Vatinel, Rodolphe,Vial, Emmanuel,Hennequin, Laurent Fran?ois
supporting information, p. 321 - 337 (2018/02/12)
With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a sought-after target in the pharmaceutical industry. Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases. These efforts culminated in the discovery of N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-[(tetrahydro-2H-pyran-4-yl)methyl]-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide (CD12681), a potent inverse agonist with in vivo activity in an IL-23-induced mouse skin inflammation model.
INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
-
Paragraph 0183; 0184; 0210, (2018/01/03)
Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR
-
Paragraph 0203, (2014/09/03)
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ wherein R1 to R7 are as defined in claim 35.
SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR
-
Page/Page column 40; 41, (2013/04/13)
The present invention is directed to novel retinoid-related orphan receptor gamma (RORy) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORy wherein R1 to R7 are as defined in claim 1.
